Edward Abrahams, PhD
Personalized Healthcare Coalition
Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC).
Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to over 225 today.
Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania's investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and Director of Government Relations at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized
Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
Back to Top
Above all else, Mark Ackerley seeks to explore and express that which is both personal and universal, chiefly through the mystique of music. Since graduating from the San Francisco Conservatory of Music in 2010, Mark has gone on to write for the Berkeley Symphony, the San Francisco Chamber Orchestra, and various other Bay Area ensembles. With the help of 23andMe and the power of consumer genomics, Mark has created a novel platform which offers customers the ability to hear their DNA in the form of a melody.
Back to Top
Joe and Retta Beery
Senior Vice President and Chief Information Officer, Life Technologies;
Joe Beery is the Chief Information Officer for Life Technologies and served the same role at Invitrogen since September 2008. Prior to Invitrogen, Joe held the executive position of Chief Information officer at US Airways and America West Airlines. Previously, Joe spent ten years at Motorola Semiconductor, holding various positions in the computer integrated manufacturing group. Joe also served as a manufacturing and software engineer at NV Philips in Albuquerque, N.M. Joe holds a BS in business administration and business computer systems from the University of New Mexico.
Retta Beery is a Patient Advocate, speaker, and runs an online support group for families dealing with rare or undiagnosed Disease. She is engaged with various medical institutions and organizations to provide support and direction in the management and care of patients with rare and undiagnosed disease. In 2002, after years of research, Retta discovered her twins had been misdiagnosed by some of the top specialists in the world. Noah and Alexis had their whole genomes sequenced in 2010 and would be one of the first cases with a positive, clinical outcome which literally saved their lives. Retta's passion and drive is to help other families navigate the medical journey of seeking diagnosis and treatment for rare and undiagnosed disease. She has a specific interest in the development of genomic sequencing as a diagnostic tool.
Back to Top
Cristie Cole, JD
Fellow, Department of Bioethics
Cristie M. Cole, JD is a 2012-2014 Fellow in the Cleveland Fellowship in Advance Bioethics, a multi-institutional program administered by the Cleveland Clinic. She received her B.A. in Biology and Society with a Concentration in Law and Society from Cornell University in 2003 and her Juris Doctorate from the University of Arizona’s James E. Rogers College of Law in 2008. Before joining the Cleveland Fellowship in Advanced Bioethics, Ms. Cole was a civil litigation attorney in California and also advised for-profit and non-profit health care companies in a variety of transactional and regulatory matters. Her research interests include the legal and ethical issues that arise from the integration of genomic technologies into clinical practice. Her current scholarship focuses on direct-to-consumer genomic testing. Ms. Cole is also actively engaged in clinical ethics consultation.
Back to Top
Thomas Daly, MD
Section Head, Clinical Pathology
Thomas Daly, MD is the section head of Immunopathology in the Robert J Tomsich Pathology and Laboratory Medicine Institute, and director of the Center for Test Development, a translational laboratory that develops and validates novel assays for clinical use. Dr. Daly received his medical degree from Washington University in St Louis, and his residency training in Clinical Pathology at Barnes-Jewish Hospital. Dr. Daly previously served as section head of Clinical Chemistry at the University of Alabama-Birmingham, and as medical advisor at Eli Lilly and Company, where he was responsible for biomarker development and validation in support of the oncology portfolio. Currently, his research interests are focused on the development and validation of novel biomarkers for clinical application, particularly in the field of personalized medicine.
Back to Top
Ahmed El-Sohemy, PhD
Associate Professor in the Department of Nutritional Sciences
University of Toronto
Ahmed El-Sohemy earned his PhD in Nutritional Sciences from the University of Toronto in 1999 and completed a postdoctoral fellowship at the Harvard School of Public Health. He joined the faculty at the University of Toronto in 2000 to establish a research program in nutrigenomics. The goal of his research is to identify biomarkers of dietary exposure and elucidate the genetic basis for variability in nutrient response and dietary preferences. He collaborates with researchers across Canada as well as the US, Costa Rica, Denmark, Italy, Switzerland, South Korea and Singapore. Dr. El-Sohemy has published over 90 peer-reviewed articles and has given over 100 invited talks around the world. He is on the editorial board of 10 journals, and served as an expert reviewer for more than 30 different scientific and medical journals and 12 granting agencies. He has served on international expert advisory panels and scientific advisory boards of several organizations, and was appointed to Health Canada's Scientific Advisory Board. Last year, he founded Nutrigenomix Inc. and serves as Chief Science Officer. Dr. El-Sohemy is currently an Associate Professor in the Department of Nutritional Sciences and holds a Canada Research Chair in Nutrigenomics.
Back to Top
Benjamin Gaston IV, MD
Division Chief, Pulmonary Diseases
UH Rainbow Babies and Children’s Hospital
Dr. Gaston is a pediatric pulmonologist at the Rainbow Babies and Children’s Hospital in Cleveland. He studies novel signaling pathways downstream of nitric oxide synthase activation that are relevant to specific subpopulations of patients with asthma, cystic fibrosis, pulmonary hypertension and apnea. He has long been an advocate for personalized medicine. Though he has only recently moved from the University of Virginia to Cleveland, he has collaborated for many years with physicians at Case Western Reserve University and Cleveland Clinic to identity phenotypically distinct and treatable severe asthma subpopulations. He and his collaborators have established several companies, two of which are well-positioned to develop and to use biochemical challenge testing to help individualize the management of severe asthma. He also has developed methods to identify individualized treatments for subsets of patients with other categories of childhood respiratory disease. His research group can be contacted through http://www.titusgroup.org/
. Back to Top
Founder and Managing Partner
Harry Glorikian heads Scientia Advisors with 20 years of experience in the health care and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth.
Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Harry has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia's sophisticated framework and proprietary analytic tools.
A sought-after speaker, Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, the Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets.
Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.
Back to Top
David Heimbrook, PhD
Chief Executive Officer
As Chief Executive Officer of SAIC-Frederick, which operates Frederick National Laboratory for Cancer Research on behalf of the National Cancer Institute, Dr. Heimbrook leads a technology-driven Federally Funded Research and Development Center (FFRDC) supporting the NCI's mission at Frederick, MD. He is responsible for the comprehensive management and oversight of all scientific, operational, and business activities conducted at Frederick National Laboratories.
Dr. Heimbrook brings more than 20 years of experience and progressive responsibility in cancer research, translational medicine and organizational management to this position. Prior to joining SAIC-Frederick in 2011, he was the global head of Discovery Oncology for the Pharma Research and Early Development (pRED) organization at Roche, where he worked for 8 years. Prior to joining Roche, Dr. Heimbrook was the head of Cancer Research at Merck, based in West Point, PA, where he worked for 16 years. Dr. Heimbrook has helped transition over a dozen molecules from research into clinical development and led internal discovery efforts at Roche supporting the development of vemurafenib, which was recently approved for the treatment of patients with metastatic melanoma harboring a specific genetic mutation. Dr. Heimbrook earned a Bachelor's degree in Chemistry from Duke University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University. He has co-authored 6 patents and over seventy (70) scientific publications.
Back to Top
Anthony John Iafrate, MD, PhD
Department of Pathology
Massachusetts General Hospital
Dr. Iafrate is a board-certified Pathologist who joined the MGH staff in 2005 and directs a clinical laboratory for molecular diagnostics at MGH and oversees a translational research laboratory that supports both Pathology and the MGH Cancer Center. He is an MD-PhD having received his dual degree from the State University of New York at Stony Brook in 2000 and was trained in Anatomic and Molecular Genetic Pathology at Brigham and Women’s Hospital. His post-doctoral work involved the discovery and description of a novel source of human genetic diversity termed copy number variation (CNV). Since arriving at MGH, he has established a cancer diagnostics lab focusing on genetic fingerprints that help guide novel “targeted” therapies. His laboratory launched Snapshot several years ago, an assay that tests over 100 of the most common mutations in tumors. His research is focused on lung and brain tumors, and he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK-positive lung cancers.
Back to Top
Jean Jenkins, PhD, RN, FAAN
Genomic Healthcare Branch
National Human Genome Research Institute
Dr. Jean F. Jenkins is a Clinical Advisor, Genomic Healthcare Branch, Division Communication, Policy, and Education, NHGRI, NIH. She received her B.S.N. from the University of Maryland, M.S.N. at the Catholic University of America, and Ph.D. from George Mason University, Va. Recognizing the importance of advances in genetics research for all health care, Dr. Jenkins strives to educate health professionals and the public about implications of genomic information for education, practice, and research. Dr. Jenkins provided leadership in the development and revision of National Coalition for Health Care Professional Education in Genetics (NCHPEG) core competencies in genetics. Building on these efforts she along with Dr. K. Calzone coordinated the development and consensus of the Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics (2005; 2009) leading to the development of an education resource repository (http://www.g-2-c-2.org/
) and a web-based case-scenarios resource (http://www.g-3-c.com/
). Dr. Jenkins has > 125 publications including three Journal of Nursing Scholarship series on genomics (2007; 2011; 2013).
Back to Top
Eric Klein, MD
Chair, Glickman Urological and Kidney Institute
Eric A. Klein, MD, is a urological oncology surgeon and Chairman of the Glickman Urological and Kidney Institute and Professor of Surgery in the Cleveland Clinic Lerner College of Medicine. Dr. Klein came to the Clinic in 1989 after a fellowship at Memorial Sloan Kettering Cancer Center. He is a member of the Cleveland Clinic Taussig Cancer Center. He also is a member of the Case Comprehensive Cancer Center and Professor of General Medical Sciences at the Case School of Medicine. He is one of America's foremost authorities on prostate cancer treatment and research. He has presented at over 160 national and international meetings and written over 231 original articles. He has also written several books on urological malignancies and has been listed in Best Doctors in America
since 1996. Dr. Klein is a co-discoverer of XMRV, a human virus found in men genetically predisposed to prostate cancer.
Back to Top
Kandice Kottke-Marchant, MD, PhD
Chair, Pathology and Laboratory Medicine Institute
Dr. Kottke-Marchant is Chair, Pathology and Laboratory Medicine Institute and Section Head of Hemostasis and Thrombosis in the Clinical Pathology Department at the Cleveland Clinic, Cleveland, OH. She also is Chair, Department of Pathology at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University as well as Adjunct Professor, Dept. of Biomedical Engineering at Case Western Reserve University, Cleveland, OH. Her current research is on hemostasis, particularly genetic determinants of aspirin and clopidogrel response. She is the author and co-author of over 250 articles, abstracts, and book chapters. She is now Past- President of the International Society for Laboratory Hematology (ISLH), where she has served as Executive Secretary from 2002 to 2008 and President from 2008 to 2011. She has currently edited a new textbook on laboratory hematology practice which is now in press. She serves on the American Board of Pathology, the Coagulation Resource Committee of the College of American Pathologists (CAP) and the Hematology Area Committee of the Clinical and Laboratory Standards Institute (CLSI). Dr. Marchant is a member of the Cleveland Clinic's Board of Governors (since 1/2009) and serves as a member of the Steering Committee for the Women's Professional Staff Association (WPSA) at the Cleveland Clinic (since 3/2008). Dr. Marchant holds M.D. and Ph.D. degrees from Case Western Reserve University, Cleveland, OH.
Back to Top
Felicitas L. Lacbawan, MD
Section Head of Molecular Genetics Pathology
Felicitas L. Lacbawan, MD, FCAP, FACMG, is the Section Head of Molecular Genetics Pathology, Department of Molecular Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute and the Program Director for the Molecular Genetic Pathology Fellowship at the Cleveland Clinic. Before 2012, Dr. Lacbawan worked in several institutions including the National Human Genome Research Institute of the National Institutes of Health, Children’s National Medical Center, Georgetown University Medical Center, and State University of New York Downstate Medical Center in various capacities as a Clinical Geneticist and a Molecular Genetic Pathologist. She pioneered two CLIA/NYSDOH certified molecular diagnostic laboratories. At the Cleveland Clinic, she leads the Section that provides molecular tests for a full range of indications spanning inherited and genetic disorders to pharmacogenomics including preventive, diagnostic, prognostic, therapeutic or predictive drug use. Her researches include clinical and molecular genetics of various neurologic and developmental disorders including presenile dementia, brain and craniofacial malformations, chromosomal anomalies, and pharmacogenomics. She is currently a member of the College of American Pathologists Subcommittee on Biochemical and Molecular Genetics and the American College of Medical Genetics Professional and Practice Guidelines Committee.
Back to Top
Brandie Leach, MS, CGC
Genetic Counselor, Genomic Medicine Institute
Brandie Heald Leach, MS, is a certified genetic counselor at the Cleveland Clinic. She has been practicing there since 2006 upon graduating from the University of Cincinnati Graduate Program in Genetic Counseling. Ms. Leach counsels patients with or at risk for hereditary cancer syndromes, especially hereditary colon cancer conditions. In 2007 she established genetic counseling services within the Digestive Disease Institute at the Cleveland Clinic. She also coordinates the Cleveland Clinic institution-wide MSI testing program, and conducts research on the hamartomatous polyposis syndromes and Barrett's esophagus. She has served in various leadership positions within the National Society of Genetic Counselors and is on the Collaborative Group of the Americas on Inherited Colorectal Cancer Council. Ms. Leach is a member of the Cleveland Clinic Commission on Cancer Committee.
Back to Top
Frederick Lee, MD, MPH
Director of Clinical & Translational Informatics
Oracle Health Sciences
Fred leads business development strategies in clinical & translational informatics and personalized healthcare
for Oracle's Health Sciences Global Business Unit. He has helped establish and grow the burgeoning field of
personalized healthcare through his ability to merge perspectives from the life sciences, healthcare delivery,
clinical informatics, and public health.
Prior to Oracle, Fred was the Founding Executive Director & Chief Medical Officer of the P4 Medicine
Institute, a translational innovation consortium dedicated to creating a predictive, preventive, personalized,
& participatory future of healthcare. In this role, he helped establish Lee Hood's vision of P4 Medicine by
developing partnerships between systems biology & major academic health centers. He continues to play a
key role in P4 Medicine, as the first official fellow of the P4 Medicine Institute.
Fred brings a unique and broad range of professional experiences to the task of creating healthcare of the
future, having spent time as a practicing clinician, as a healthcare executive, and as an industry technologist.
From the industry perspective, Fred led product strategy efforts for McKesson Corporation in its Provider
Technologies division, focusing on enhancing electronic health records to support genomic & molecular
medicine. He has also held leadership roles in General Electric Healthcare, leading product strategy for GE
Healthcare Information Technologies in the United Kingdom while working on the UK's National Health
Service Connecting for Health program.
Fred has held executive leadership roles in health systems in the New York / Long Island area, as a Chief
Operating Officer and as a Chief Medical Information Officer of a large ambulatory care network in New York.
Fred's clinical background is in general surgery and preventive medicine. He received a BS from the
Massachusetts Institute of Technology in Life Sciences, an MD and residency training from the Stony Brook
University School of Medicine, and a Masters in Public Health degree from the Mailman School of Public
Health at Columbia University.
Back to Top
David Levin, MD
Chief Medical Operations Officer,
David Levin, M.D. is Chief Medical Information Officer for the Cleveland Clinic Health System.
His current focus includes information systems, knowledge management and clinical transformation. He has over 20 years of experience in diverse areas including quality improvement, patient safety, hospital and group practice operations, credentialing, and population management. He also brings to bear over 25 years of experience in Information Technology and has worked with a wide variety of clients in the development of clinical and educational IT applications.
From 2008 to 2011, Dr. Levin served as the Vice President for Medical Informatics (CMIO) for Sentara Healthcare, a non-profit integrated delivery system based in Virginia. During that time Sentara implemented regional health information organization based on the EPIC EMR, achieved HIMSS Analytics Level 7 certification and won the HIMSS Davies Award (2010).
Dr. Levin holds degrees in Biology and Medicine from Brown University. He completed his residency in Family & Community Medicine at Brown in 1991 and a fellowship in academic Family & Community Medicine at Eastern Virginia Medical School (EVMS) in 1994. He is also a former Vice Chairman for Clinical Affairs in the Department of Family and Community Medicine at EVMS.
Dr. Levin also serves on multiple Boards of Directors including The Comprehensive Health Investment Project (CHIP) of Virginia and Chesapeake Bay Academy. He is married to Dr. Beth Levin, an obstetrician-gynecologist.
Back to Top
David Longworth, MD
Chair, Medicine Institute
David L. Longworth, MD is Chair of the Medicine Institute at Cleveland Clinic. He received his undergraduate degree from Williams College and his medical school degree from Weill Cornell University Medical College. He completed training in Internal Medicine at the University of California in San Francisco followed by fellowship training in Infectious Diseases at Harvard Medical School and Brigham and Women's and Beth Israel Hospitals. Dr. Longworth joined the Cleveland Clinic in 1986 as a staff physician in the Department of Infectious Diseases. From 1992–2002 he served as Chair of the Department. He subsequently moved to Baystate Medical Center, the western campus of Tufts University School of Medicine, where he served as Chair of the Department of Medicine and as Professor and Deputy Chair of the Department of Medicine at Tufts University School of Medicine. He returned to the Cleveland Clinic as Chair of the Medicine Institute in 2011.
Back to Top
Partner, Health and Life Sciences
Michael is a seasoned healthcare consultant and Partner at Oliver Wyman’s Health and Life Sciences practice. He currently leads the Health and Life Science’s Healthcare Reform oriented Health Plan Strategic Growth practice. Michael’s experience spans a myriad of engagement topics from corporate strategy, top-line growth, Integrated Health Management, mergers and acquisitions and organizational change management. An alumnus of the J. L. Kellogg Graduate School of Management at Northwestern University, Michael is an exemplary healthcare strategist, nationally recognized speaker and author.
- Developed long range strategic plan and clinical delivery system blueprint for Integrated Delivery System which is driving significant medical cost savings, achieving unrealized efficiencies and gained recognition for its innovation and impact on clinical quality and affordability.
- Led regional health plan transformation from legacy HMO to consumer centric Health Management Company resulting in record revenue and margin performance year over year four years running.
- Innovated marketing and sales processes for national health plan leading to significant revenue performance improvements, lower cost of sales and more durable profitable retention.
- Designed national product launch strategy which resulted in the health plan over- taking rival companies’ two year head start and early mover share advantage.
- Redefined Medical Management organization’s market approach, product-pricing structure and market position to reestablish the company as leading growth company from stagnant revenue and margin performance.
- Built strategic roadmap for national growth and expansion plan for leading self-funded administrator resulting in record growth and profit performance.
- Authored series of research studies and white papers on the impact of Healthcare Reform on distribution, exchange-based marketing and retail consumer markets.
- Formulated new structural design, product portfolio rebalancing and go to market strategy for national health plan’s internal and external Medical Management company.
Michael is a captivating speaker and is known for his ability to blend story telling, and practical insights with thought provoking inspirations. He lives in Naperville IL and is an avid skier, triathlete and outdoor enthusiast.
Back to Top
Chief Business Officer
As an entrepreneur, a political advisor and a technologist, Mr. Marrazzo has been at the center of government-led healthcare reform efforts and on the cutting edge of medicine as a start-up executive in the field of personalized medicine.
Today, Mr. Marrazzo serves as chief business officer for MolecularHealth, a treatment decision support company that provides solutions for oncologists seeking to translate complex clinical and molecular data into safer, more effective drug options for their cancer patients. MolecularHealth’s work with leading cancer centers such as the University of Texas MD Anderson Cancer Center is helping to match cancer patients’ genomes with the best available drugs or clinical trials available to them. Mr. Marrazzo guides the company’s business strategy and commercial operations and recently formed its collaboration with the U.S. Food and Drug Administration.
Prior to MolecularHealth, Mr. Marrazzo was a part of the founding team at Generation Health, the first company in a new field of genetic benefit management – helping healthcare payers optimize the use of genetic testing – up to and following the acquisition of a majority of the company’s shares by CVS Caremark. There, he is credited with having built the company’s initial customer base of self-insured employer clients and the first-ever network of genetic testing labs.
Previously, Mr. Marrazzo was a senior member of the business development and finance teams at Tengion (TNGN), a clinical-stage regenerative medicine company that went public in April 2010. Mr. Marrazzo has also worked at the highest levels of government as a healthcare advisor to Pennsylvania Governor Edward G. Rendell and at IBM Business Consulting Services as a management consultant to global pharmaceutical companies. During his career, Mr. Marrazzo has advised physician executives at The Children’s Hospital of Philadelphia and investment firms such as Safeguard Scientifics (SFE). He is currently a Director of Vigilant Biosciences.
Mr. Marrazzo graduated magna cum laude from the University of Pennsylvania with bachelor’s degrees in engineering and economics and holds a dual master’s degree in business and public administration from Wharton and Harvard, a cross-institutional program which he founded.
Back to Top
Executive Director, Market and Network Services
Michael McMillan is the Executive Director of Market and Network Services for Cleveland Clinic, a 6 billion dollar healthcare system with operations in Ohio, Florida, Nevada, and around the globe. He is responsible for all aspects of the business relationship with health plans and employers, including managed care business development, network management, pricing, contracting and direct sales for Cleveland Clinic's world class products and services. Within this scope, Mr. McMillan is accountable for developing Cleveland Clinic's value-based approach to healthcare as the organization continues its leadership role within a changing industry. Mr. McMillan is also the President of the Cleveland Clinic Community Physician Partnership, a 1000 physician network of independent community based physicians.
Mr. McMillan earned his undergraduate and graduate degrees from Columbia University in New York.
Back to Top
Heidi L. Rehm, PhD, FACMG
Harvard Partners Center for Genetics
Harvard Medical School
Heidi L. Rehm, PhD, FACMG is the Chief Laboratory Director for the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine and Assistant Professor of Pathology at Harvard Medical School. She was recruited in 2001 to build the CLIA lab after completing her graduate degree in Genetics from Harvard University and her postdoctoral and fellowship training at Harvard Medical School. The lab focuses on the rapid translation of new genetic discoveries into clinical tests that can be used to improve patient outcomes, supporting the model of personalized medicine. The lab also focuses on bringing novel technologies and software systems into molecular diagnostics to support the integration of genetics into clinical use. The laboratory has been a leader in translational medicine, launching the first clinical tests for cardiomyopathy and lung cancer treatment among many others. In 2013, the lab will launch a CLIA-approved interpretive service for whole genome sequencing. Dr. Rehm is also involved in defining standards for the use of next generation sequencing in clinical diagnostics through her committee roles at the American College of Medical Genetics and collaborative efforts with the CDC. Dr. Rehm is also involved in a major effort to develop and curate a universal human genetic variant database through collaborative efforts with NCBI and other organizations. Dr. Rehm also conducts research in hearing loss, Usher syndrome, genomic medicine, and healthcare IT.
Back to Top
Mary V. Relling, PharmD
Chair, Pharmaceutical Sciences
St. Jude Children's Research Hospital
Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and in 2003 was named chair of the Department of Pharmaceutical Sciences. She is also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy.
Her primary interests are in treatment of childhood leukemia and pharmacogenetics of antileukemic therapy. Dr. Relling is one of the Principal Investigators within NIH's Pharmacogenomics Research Network and co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 240 original scientific manuscripts. She was elected to the Institute of Medicine in 2009.
Back to Top
Michael Roizen, MD
Chief Wellness Officer,
Michael F. Roizen, MD, has founded or cofounded 12 companies, co-invented a drug and four #1 NY Times bestsellers. He is the first Chief Wellness Officer at any major academic medical center, Cleveland Clinic. He is the cofounder of RealAge, Inc. He has published more than 170 peer-reviewed scientific papers, 100 chapters, 30 editorials, and 4 medical books, and received 13 U.S. patents. He is boarded in Internal Medicine and Anesthesiology.
Dr. Roizen has given over 1,400 lectures, has appeared on Oprah, Today, 20/20, CBN, Good Morning America , Canada AM, more than 18 times each and has four PBS fundraising specials. He and Mehmet Oz write a daily syndicated newspaper column which appears in over 130 newspapers. He also has a 2-hour 26 station Terrestrial radio show.
Back to Top
Miss District of Columbia 2012
Allyn Rose won the title of Miss District of Columbia 2012 on June 17, 2012, and will compete in the 2013 Miss America pageant in January 2013. She also represented Maryland in the 2011 Miss USA pageant, placing in the Top 8.
After losing her mother to breast cancer at the age of 16, Rose has partnered with the Susan G. Komen Breast Cancer Foundation, Tigerlilly Foundation and Dig Pink, educating youth and adults on cancer awareness and prevention. Her platform for the Miss America Organization is Breast Cancer: Planning a Marathon, Running a Sprint.
Rose was a competitive roller figure skater and won her first USA Roller Sports (USARS) championship at the age of 12. She will perform an artistic roller skating routine for the talent competition at the Miss America pageant.
Rose attended La Plata High School in La Plata, Maryland, where she was an active member of student government and a decorated athlete. She was a 1st team all-conference volleyball player and track and field athlete. Rose went on to play volleyball for the College of Southern Maryland, where the CSM Hawks ranked 2nd in the MDJUCO Conference in 2006 and later at the University of Maryland, College Park, where she graduated with a B.A. in Government & Politics and a concentration in Political Philosophy.
Currently pursuing her career goal of becoming a constitutional attorney, Rose is a paralegal for a law firm. She also works as a model and can be seen in national ad campaigns for companies such as CHI by Farouk Systems, WEN by Chaz Dean, Sherri Hill, Rain Cosmetics, OPI Nailcare, Australian Gold, and other on-air clients for the QVC Network.
Back to Top
Raul Seballos, MD
Vice-Chairman, Preventive Medicine Department
Raul J Seballos, MD, FACP joined Cleveland Clinic in 1997 following two years of private practice in internal medicine. A graduate of Case Western Reserve University (BA Chemistry, 1983), he earned his medical degree at The Medical College of Ohio at Toledo. He completed his residency training in internal medicine at St. Luke's Medical Center and served a fellowship in pulmonary and critical care medicine at the Cleveland Clinic. Dr. Seballos is the Vice-Chairman of the Preventive Medicine Department of the Wellness Institute. He currently practices preventive medicine at the Cleveland Clinic's Executive Health Program (www.clevelandclinic.org/executivehealth
) and participates in the evaluation of adults with attention-deficit hyperactivity disorder.
Dr. Seballos is certified by the American Board of Internal Medicine and is a Fellow of the American College of Physicians. He was elected by his peers for inclusion in Best Doctors in America® in 2007. In 2009, Dr. Seballos received a "Service Excellence Award", presented annually to 10 physicians nationwide who have demonstrated an extremely high level of integrity and compassionate care to Healthnetwork members. In 2011, Dr. Seballos was honored with "The Richard S Lang, MD Distinguished Chair in Preventive Medicine" established by Maria and Sam Miller, and Audrey and Albert Ratner. His primary interests are preventive medicine, cardiovascular risk assessment, cancer screening, men's health, and adult attention-deficit hyperactivity disorder.
Dr. Seballos currently serves as a reviewer for the Cleveland Clinic Journal of Medicine and is an Advisory Board member for the Cleveland Clinic's Men's Health Advisor
. He is the Preventive Medicine Section Editor for the textbook, Cleveland Clinic's Current Clinical Medicine
Back to Top
Richard Sharp, PhD
Director, Bioethics Research,
Department of Bioethics
Dr. Richard Sharp is Associate Director of Research and Education in the Center for Ethics, Humanities and Spiritual Care at Cleveland Clinic and Co-Director of the Center for Genetic Research Ethics and Law at Case Western Reserve University, one of six NIH Centers of Excellence in Ethics Research. Prior to joining Cleveland Clinic in 2007, Dr. Sharp worked at the Center for Medical Ethics and Health Policy at Baylor College of Medicine and at the National Institute of Environmental Health Sciences, one of the National Institutes of Health. Dr. Sharp's research focuses on how patients and healthcare providers view the potential benefits and risks of genetic technologies, including new diagnostic technologies (R01 HG004500) and clinical interventions enabled by molecular diagnosis (R01 HG004877). He is also interested in the translation of genomic findings into health policy and is the lead editor of Genomics and Environmental Regulation: Science, Ethics, and Law published by Johns Hopkins University Press.
Back to Top
Gregory Stock, PhD
Chief Science Officer and Executive Director
Gregory Stock, the co-founder and CSO of Ecoeos, founded Signum Biosciences, which is developing therapeutics for Alzheimer's, and the Program on Medicine and Technology at UCLA's School of Medicine. His book, Redesigning Humans: Our Inevitable Genetic Future, won the Kistler Book Prize for Science books. He also wrote Engineering The Human Germline, Metaman, and The Book of Questions, which now has been translated into 19 languages. Stock sits on the editorial boards of The Journal of Evolution and Technology, and Rejuvenation Research. He has debated biotech policy with Jeremy Rifkin, Leon Kass, Francis Fukuyama and other key figures, and sits on the California Advisory Committee on Stem Cells and Reproductive Cloning. Stock has a Ph.D in Biophysics from Johns Hopkins and an MBA from Harvard.
Back to Top
Kathryn Teng, MD, FACP
Director, Center for Personalized Healthcare
Kathryn Teng, MD, FACP is Director, Center for Personalized Healthcare at Cleveland Clinic. She is a Staff Physician in the Medicine Institute at Cleveland Clinic. Dr. Teng is also an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western University.
Dr. Teng joined Cleveland Clinic in 2007 following a faculty appointment at Harvard Medical School and Massachusetts General Hospital, where she served as assistant medical director for her group practice. She completed her internship in Obstetrics and Gynecology at Vanderbilt University Medical Center, and her internship and residency in Internal Medicine at Vanderbilt University Medical Center. Dr. Teng is board-certified in Internal Medicine.
She is committed to leading Cleveland Clinic's efforts to integrate personalized healthcare approaches into the standard practice of medicine.
Back to Top